Barclays raised the firm’s price target on Viatris (VTRS) to $17 from $15 and keeps an Overweight rating on the shares. The “muted reaction” to Viatris’ investor day is unsurprising given the macro environment, the analyst tells investors in a research note. The firm says that while it understands the lower EBITDA growth outlook, the stock trades at “just” 6-times. Viatris’ revenue upside and pipeline are not fully appreciated at current shred levels, contends Barclays.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTRS:
- Viatris announces approval for Effexor SR 37.5 mg / 75 mg capsules in Japan
- Viatris outlines vision for growth through 2030
- Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
- Unusually active option classes on open March 12th
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 8